Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Gynecologic 1

Conditions

Carcinoma, Renal Cell 65Kidney Neoplasms 18Neoplasms 16Neoplasm Metastasis 10Carcinoma, Non-Small-Cell Lung 10Colorectal Neoplasms 8Carcinoma, Hepatocellular 8Carcinoma 8Melanoma 7Glioblastoma 5Clear-cell metastatic renal cell carcinoma 5Lung Neoplasms 4Uterine Cervical Neoplasms 3Recurrence 3Ovarian Neoplasms 3Endometrial Neoplasms 3Thyroid Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Solid Tumors 2Skin Neoplasms 2Sarcoma 2Pheochromocytoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Paraganglioma 2Liver Neoplasms 2Kidney Diseases 2Carcinoma, Adenoid Cystic 2Breast Neoplasms 2Advanced Solid Tumors 2

Interventions

Trastuzumab 628Paclitaxel 577Cyclophosphamide 555Docetaxel 485Capecitabine 402Letrozole 376Fulvestrant 327Doxorubicin 294Carboplatin 279Tamoxifen 275Anastrozole 243exemestane 228Radiotherapy 218Epirubicin 211Bevacizumab 196palbociclib 189pertuzumab 186Vinorelbine 167Lapatinib 167Gemcitabine 166pembrolizumab 162Surveys and Questionnaires 139Exercise 136Magnetic Resonance Spectroscopy 123Fluorouracil 119Blood Specimen Collection 118eribulin 117Albumin-Bound Paclitaxel 117Drug Therapy 111130-nm albumin-bound paclitaxel 111

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Breast Neoplasms × Axitinib × Clear all
NCT05904730 2024-12-30

Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations

Lynkcell Europe

Phase 1 Completed
10 enrolled
BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT00076024 2012-06-26

AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast Cancer

Pfizer

Phase 1/2 Completed
174 enrolled 14 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡